PIPELINE & PRODUCT CATEGORIES

ONCOLOGY

Preclinical

Phase 1

Phase 2

Phase 3

Phase 4

BCM-0644

Indication – Melanoma, SSC, BBC | Formulation – Oral and Topical

BCM-5228

Indication – Various | Formulation – Intravenous

ANTIFUNGALS

Preclinical

Phase 1

Phase 2

Phase 3

Phase 4

BCM-0882

Indication – Candida auris (Antimicrobial Resistant) | Formulation – Oral and Topical

BCM-0915

Indication – Candida albicans (Antimicrobial Resistant) | Formulation – Oral and Topical

BCM-1034

Indication – Various | Formulation – Intravenous

ANTIBIOTICS

Gram-Positive

Preclinical

Phase 1

Phase 2

Phase 3

Phase 4

BCM-0184

Indication – Staphylococcus aureus – methicillin resistant (MRSA) | Formulation – Oral and Topical

BCM-0146

Indication – Enterococcus faecalis – vancomycin resistant (VRE) | Formulation – Oral and Topical

BCM-0168

Indication – Streptocuccus pneumoniae – MDR | Formulation – Oral and Topical

BCM-1032

Indication – Various | Formulation – Intravenous

Gram-Negative

BCM-0242

Indication – Carbapenem-resistant enterobacteriaceae (CRE) | Formulation – Oral and Topical

BCM-0218

Indication – Neisseria gonorrhoeae – DR | Formulation – Oral and Topical

BCM-0250

Indication – Pseudomonas aeruginosa – MDR | Formulation – Oral

BCM-0252

Indication – Shigella – DR | Formulation – Oral and Topical

DERMATOLOGY

Preclinical

Phase 1

Phase 2

Phase 3

Phase 4

BCM-0782

Indication – Acne vulgaris | Formulation – Topical

BCM-0718

Indication – Pruritus | Formulation – Topical

Find out more about Biocidium’s three focus areas of medical research:

ANTIBIOTICS
ANTIFUNGALS
ONCOLOGY